Neurizon Therapeutics Limited has released a press release.
Final Ethics Approval for Open-Label MND Extension Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Media clarification
- Pause in Trading
- Positive clinical data filed with FDA to support ODD request
- Appendix 4D & Half-Year Report
- Positive Phase 1 MEND Study Top-Line Results
Later from Neurizon Therapeutics
- Resignation of Dr Michael Thurn & appointment of John Clark
- Board Changes
- PharmAust receives Orphan Drug Designation for monepantel
- Executive team strengthened, appointment of MD/CEO & new CSO
- OLE Study update reveals impressive Survival Data
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics